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Background: Although repetitive transcranial magnetic stimulation (rTMS) has been
assessed in epileptic humans, clinical trials in epileptic dogs can provide additional
insight.
Objectives: Evaluate the potential antiepileptic effect of rTMS in dogs.
Animals: Twelve client-owned dogs with drug-resistant idiopathic epilepsy (IE).
Methods: Single-blinded randomized sham-controlled clinical trial (dogs allocated to
active or sham rTMS) (I) and open-labeled uncontrolled clinical trial (dogs received
active rTMS after sham rTMS) (II). Monthly seizure frequency (MSF), monthly seizure
day frequency (MSDF), and number of cluster seizures (CS) were evaluated for a
3-month pre-TMS and post-rTMS period and safety was assessed. The lasting effect
period of rTMS was assessed in each dog treated by active stimulation using the
MSF ratio (proportion of post-TMS to pre-rTMS MSF) and treatment was considered
effective if the ratio was <1.
Results: No adverse effects were reported. In trial I, MSF and MSDF decreased sig-
nificantly (P = .04) in the active group (n = 7). In the sham group (n = 5), no significant
changes were found (P = .84 and .29, respectively). Cluster seizures did not change
significantly in either group. No significant differences were detected between the
groups. In trial II, previously sham-treated dogs (n = 5) received active rTMS and sig-
nificant decreases in MSF and MSDF were noted (P = .03 and .008, respectively). The
overall effect of rTMS lasted for 4 months; thereafter, the MSF ratio was >1.
Conclusions and Clinical Importance: Repetitive transcranial magnetic stimulation
may be a safe adjunctive treatment option for dogs with drug-resistant IE, but large-
scale studies are needed to establish firm conclusions.
Abbreviations: AEDs, antiepileptic drugs; CMAPs, compound muscle action potentials; CRI, constant rate infusion; CS, cluster seizures; MSDF, monthly seizure day frequency; MSF, monthly
seizure frequency; rTMS, repetitive transcranial magnetic stimulation.
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1 | INTRODUCTION
Idiopathic epilepsy (IE) is a common neurological disorder, with an
estimated prevalence of 0.5% to 0.82% in the general canine popula-
tion, and up to 33% in certain families of genetically predisposed
breeds.1-7 Drug resistance occurs in up to 30% of the dogs with IE
leading to a grave prognosis and eventually euthanasia because of lim-
ited nonpharmacological treatment options.8 Repetitive transcranial
magnetic stimulation (rTMS) has received attention the recent years
as a treatment method that can have neuromodulatory effects on the
brain that last longer than the duration of the neurostimulation.9
Although the specific antiepileptic mechanism of action still remains
unclear,10 it might be related to the disruption of networks related to
cortical hyperexcitability.11,12 Clinical trials of low-frequency rTMS in
drug-resistant epilepsy in humans however had conflicting outcomes
with regard to the decrease in seizure frequency.13-15 Because dogs
with spontaneous epilepsy are similar in etiology, clinical manifesta-
tion, treatment response, and drug resistance to epileptic
humans,16-19 a preliminary veterinary study was conducted to
(a) investigate this new, noninvasive, and nonpharmacological treat-
ment option for dogs with drug-resistant IE and (b) provide prelimi-
nary information for future large-scale clinical trials in dogs that could
establish firm conclusions regarding its effect in IE of dogs and a
potential use as a translational model for epileptic humans.
2 | MATERIAL AND METHODS
Dogs with drug-resistant IE without age, breed, or sex limitations
were considered for enrollment in the study. The classification, defini-
tion, and diagnosis of IE were based on the recommendations of the
International Veterinary Epilepsy Task Force (IVETF) consensus
reports.20,21 Drug-resistant IE, in particular, was defined as epilepsy
with <50% decrease in monthly seizure frequency (MSF) compared to
baseline after treatment with at least 2 antiepileptic drugs (AEDs)
despite optimal dose, serum drug concentrations, or both.20,21
The study consisted of 2 trials: (I) a single-blinded randomized
sham-controlled clinical trial and (II) an open-labeled uncontrolled clin-
ical trial. Each trial consisted of 3 phases: (a) the baseline epileptic sei-
zure frequency phase (ie, a 3-month pretreatment follow-up period of
epileptic seizures to determine baseline seizure frequency and number
of cluster seizures [CS], defined as ≥2 epileptic seizures over a period
of 24 hours22); (b) the treatment period (ie, daily treatment using
active or sham [inactive] rTMS for 5 consecutive days); and, (c) the
evaluation period (ie, a minimum 3-month posttreatment follow-up
period of epileptic seizure frequency and adverse events related to
treatment). After the initial evaluation period of 3 months, dogs
treated using active rTMS were followed as long as possible until
study termination. During phases (a) and (c), owners recorded epileptic
seizure events in a diary.
The study was approved by the university's ethical committee
(EC 2016/30). Owner consent forms were provided and signed by the
owners. The overall timespan of recruitment was 12 months.
2.1 | Trial I
At the end of phase (a), dogs were randomly assigned to the active or
sham rTMS group by using sealed envelopes. Equal numbers of
entries indicating either active or sham rTMS were created and placed
in envelopes. The envelopes were sealed, mixed, and randomly num-
bered. They were opened for each included dog following a numerical
sequence starting from envelope number 1. The investigators did not
know the randomization order. Owners were blinded to the chosen
treatment (ie, owners were not informed about which treatment their
dog would receive). The dogs were hospitalized for 5 days or on con-
secutive afternoons and all received sedation and IV catheters while
the procedure was initiated and after the owners had left the hospital.
Blood samples for CBC and serum biochemistry as well as AED serum
concentration assessment were collected from all dogs at that time.
During phase (b), the dogs received rTMS (active or sham) for
1 hour daily for 5 consecutive days. Overall, stimulation parameters
and study environment were exactly the same in both groups, the
only difference being that the sham group received inactive stimula-
tion by placing the operating (round) coil perpendicular to the skull
and with a distance of 20 cm above the head in order to circumvent
brain stimulation. Dogs in both groups were sedated using
dexmedetomidine 1 μg/kg (Dexdomitor; Orion pharma, Finland) and
butorphanol 0.1 mg/kg (Dolorex; Intervet, Belgium) IV after catheter
placement, and were kept under sedation during treatment using a
dexmedetomidine constant rate infusion (CRI) of 1 to 3 μg/kg/h. The
length of sedation was the same in both groups. Lactated Ringer's
solution 5 mL kg/h (Vetivex VB11A; Dechra, UK) was administered
with the dexmedetomidine CRI during treatment, and butorphanol
0.1 mg/kg was repeated 1 hour after initiation of sedation. Oxygen at
2 L/min was provided to all dogs using an anesthetic mask. Cotton
earplugs were placed in the dogs' ears to avoid noise disturbances
from the rTMS machine during operation. The dogs were stabilized in
ventral recumbency on the examination table using tape to avoid
minor movements. In dogs receiving active rTMS treatment, the round
coil (outside diameter of 15 cm) was applied in parallel and in contact
with the dog's skull with its center located at the vertex (active rTMS;
Figure 1). Overheating of the coil was managed using cold packs and
fans. The stimulation parameters were 18 trains of 90 pulses per train
at a frequency of 1 Hz (ie, 1 pulse per second) and an intertrain inter-
val of 120 seconds. Coil output was individually determined in each
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patient and was chosen based on the motor cortex threshold.23 Spe-
cifically, this threshold was defined as the minimal TMS intensity
required to provoke at least 5 of 10 electromyographic responses (ie,
compound muscle action potentials [CMAPs], with an amplitude of at
least 50 μV, in a fully relaxed thoracic limb muscle [external carpi
radialis]). The CMAPs were recorded not only to determine coil output
in each patient but also to monitor stimulation of the motor cortex
during rTMS treatment (active rTMS group).
During phase (c), all owners recorded epileptic seizure events in a
diary and any potential adverse effects on a form. No AED dose
changes were made in either group during the evaluation period. At
the end of phase (c), the following variables were recorded for each
dog: MSF, monthly seizure day frequency (MSDF), and monthly num-
ber of CS.24 The MSF before and after the treatment was calculated
by counting the number of epileptic seizures per month. The MSDF
before and after the treatment was calculated by counting the number
of days with epileptic seizures per month. As such, the MSDF is less
sensitive to bias caused by clusters with a high number of epileptic
seizures. To determine the 3-month pretreatment or posttreatment
results for each dog, the MSF, MSDF, and number of CS over a period
of 3 months were added and divided by 3. These values thereafter
were used to calculate and compare each group's pretreatment and
posttreatment MSF, MSDF, and number of CS.
2.2 | Trial II
After the 3-month evaluation period of trial I, dogs from the trial I
sham group were included in trial II to receive active rTMS. The effect
of active rTMS on these dogs was assessed for an additional 3-month
evaluation period. Owners were not blinded to the treatment in trial
II. The procedure followed in each phase was the same as described
earlier for the active rTMS group in trial I.
2.3 | Statistical analysis
Statistical analysis was conducted using R version 3.5.2. Firstly, base-
line values for MSF, MSDF, and number of CS of the sham (n = 5) and
active rTMS (n = 7) group were compared using the Wilcoxon rank-
sum test. The Wilcoxon signed-rank test then was used to compare
the outcomes (MSF, MSDF, or CS) within each group as well as
between groups. Significance was set at P ≤ .05. The MSF ratio (pro-
portion of monthly post-rTMS MSF to 3-month pre-rTMS MSF) was
used to determine the duration of rTMS efficacy (if any) in each dog
treated by active rTMS. The rTMS was considered effective if the
MSF ratio remained <1.
3 | RESULTS
3.1 | Trial I
Dogs were randomized to receive either active (n = 7) or sham (n = 5)
rTMS. The difference in the number of dogs recruited between the
2 groups was a consequence of the decision of 2 owners to withdraw
from the study before their dogs could be included in the trial. At
baseline, no significant differences were found between the 2 groups
in terms of MSF (P = .8), MSDF (P = .57), number of CS (P = .78), and
general characteristics. Details of the baseline characteristics of all
dogs in each group are provided in Table 1. It was possible to record
CMAPs in all dogs stimulated by active rTMS, which successfully
determined TMS coil output. Median TMS coil output was 70%
(range, 70-80%) for the active group. Eleven of 12 dogs completed
the entire protocol, whereas 1 dog (in the active group) was eutha-
nized after 2 months in the evaluation period upon the owner's
request for reasons unrelated to the trial or treatment. In the active
group, significant differences were observed in MSF (P = .046) and
MSDF (P = .046) but not in the number of CS (P = .58) post-rTMS
compared to pre-rTMS. In the sham group, no significant differences
were observed in either MSF (P = .84), MSDF (P = .29), or number of
CS (P = .12) post-rTMS compared to pre-rTMS. These results are sum-
marized in Table 2 and Figures 2 and 3. When comparing the 2 groups,
no significant differences were found in MSF (P = .14), MSDF
(P = .25), and number of CS (P = .61) post-rTMS. Based on the MSF
ratio, the median rTMS effect lasted for 4 months (range, 2-10).
Median follow-up of dogs treated with active rTMS from inclusion to
termination of the study was 4 months (range, 2-12). In the active
group, no adverse effects were related to the 5-day treatment of low-
frequency rTMS.
3.2 | Trial II
Dogs previously treated by sham stimulation (n = 5) received active
treatment. Median TMS coil output was 75% (range, 70-90%). No
dogs were lost to follow-up. Significant differences were found in
MSF (P = .03) and MSDF (P = .008) but not in number of CS (P = .12)
F IGURE 1 A dog in the active group under sedation during rTMS
procedure. A round coil (outside diameter of 15 cm) is applied in
parallel and in contact with the dog's skull with its center located at
the vertex
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TABLE 1 Details of baseline characteristics in each group
Groups Active rTMS Sham rTMS
Number of dogs 7 5
Breed Australian Shepherd, Border Collie, Cane
Corso, Golden Retriever, French Bulldog,
Jack Russell Terrier, Italian Spinone
Beagle, Boston Terrier, Cane Corso, Golden
Retriever, American Staffordshire Terrier
Age Median, 4.3 (range, 1.9-6.5 years) Median, 3.8 (range, 3.1-9 years)
Sex/neuter status 4 intact male dogs (57%)
3 neutered female dogs (43%)
3 intact male dogs (60%)
2 neutered female dogs (40%)
Type of epileptic seizures Generalized tonic-clonic (7 dogs, 100%) Generalized tonic-clonic (5 dogs, 100%)
Tier classification Tier I (2 dogs, 28%) and tier II (5 dogs, 72%) Tier I (1 dog, 20%) and tier II (4 dogs, 80%)
Chronic/maintenance antiepileptic drugs Phenobarbital/potassium bromide
combination treatment (5 dogs, 70%) and
phenobarbital/potassium bromide/
levetiracetam combination treatment (2
dogs, 30%)
Phenobarbital/potassium bromide
combination treatment (3 dogs, 60%) and
phenobarbital/potassium bromide/
levetiracetam combination treatment (2
dogs, 40%)
Time period on multidrug treatment Median, 18 (range, 10-28 months) Median, 20 (range, 7-25 months)
Cluster epilepsy (before occurrence of
status epilepticus)
12 dogs (60%) 7 dogs (47%)
TABLE 2 Details of the 3-month MSF, MSDF, and number of cluster seizures in each group pretreatment and posttreatment with a 5-day
low-frequency rTMS
Trial I Trial II
Active rTMS (n = 7) Sham rTMS (n = 5) Active rTMS following sham (n = 5)
MSF median (range) Pre 3.33 (2.00-14.33) 7.66 (2.00-8.33) 6.33 (2.33-11.66)
Post 2.00 (.66-8.33) 6.33 (2.33-11.66) 2.66 (1.00-8.00)
MSDF median Pre 3.33 (1.66-13.00) 2.33 (1.33-7.33) 5.33 (2.33-6.66)
(range) Post 1.33 (.66-8.00) 5.33 (2.33-6.66) 2.33 (.66-5.33)
Number of CS median (range) Pre 1.00 (.00-7.00) 3.00 (.00-6.00) 1.00 (.00–6.00)
Post 1.00 (.00-3.00) 1.00 (.00-6.00) 0.00 (.00-6.00)
Abbreviations: CS, cluster seizures; MSDF, monthly seizure day frequency; MSF, monthly seizure frequency; rTMS, repetitive transcranial magnetic
stimulation.
F IGURE 2 Illustration of the 3-month pre-rTMS and post-rTMS MSF and MSDF for each dog in the active group
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post-rTMS compared to pre-rTMS. No changes in AED treatment
were made during the evaluation period. The results are summarized
in Table 2. Based on the MSF ratio, the median rTMS effect lasted for
4 months (range, 2-6). Median follow-up of the dogs from inclusion in
the active treatment group until termination of the study was
5 months (range, 3-6). No adverse effects related to the treatment
were reported.
4 | DISCUSSION
We investigated a new noninvasive and safe neurostimulation tech-
nique as a potential treatment option, adjunctive to AEDs, for dogs
with IE and obtained preliminary results from application of 5-day
low-frequency rTMS on small number of dogs with drug-resistant
IE. Our results provide an indication of the effect that can be expected
and, as such, provide an ideal starting point to perform power calcula-
tions and design future, large-scale studies to further assess the role
of this neurostimulation method in veterinary medicine.
The principle behind rTMS is Faraday's law of electromagnetic
induction.25-27 More precisely, short alternating electrical currents
pass through a stimulation coil, which generates a secondary alternat-
ing magnetic field parallel and in the opposite direction to the primary
electrical current. This field, when perpendicularly orientated to the
head, can bypass the scalp and reach the cerebrospinal fluid and brain,
unhindered by the skull and soft tissues. The magnetic field induces a
secondary electrical current, which modulates the cortical neurons
and produces the desirable neurobiological effects.28
The effects of rTMS are dependent on the frequency and pattern
of the stimuli. Alterations in the stimulation parameters (ie, number of
trains, number of pulses per train, TMS frequency, and intensity and
duration of treatment) might affect specific neuronal cells, which
could lead to selective cortical modulation adjusted for the specific
disorder targeted.29 However, no consensus currently exists on the
optimal stimulation parameters for specific diseases, such as epi-
lepsy.10 Cortical excitability can be increased or decreased using high-
frequency (>1 Hz) and low-frequency (≤1 Hz) neurostimulation,
respectively, which likely is caused by the potential induction of
long-term potentiation and depressive mechanisms, respectively.30
Although there is an overall agreement that low-frequency rTMS
supresses epileptic discharges and leads to a decrease in seizure
frequency,31-33 the remaining stimulation parameters are quite vari-
able in trials of human patients.10 With regard to the pulses, more
pulses per rTMS session were associated with higher efficacy.34 As
far as the duration of treatment is concerned, rTMS has an effect
that outlasts the duration of the treatment, which can be attributed
to consecutive sessions.14,35,36 In 1 study, neuroplastic long-lasting
changes were observed when at least 2 rTMS sessions were admin-
istered within 24 hours, but not when administered 1 week apart.35
In addition, the effects of low-frequency rTMS on cortical excitabil-
ity were dependent on the intensity used.37 In 1 study, high rTMS
intensity (90%) was found to be superior and significantly decreased
seizure frequency, compared to low-intensity rTMS (20%),38
whereas another study found good antiepileptic rTMS effect with
relatively high intensity (70%).14 In our study, 1-week (5 consecutive
days), low-frequency (1 Hz), high-intensity (≥70%) rTMS with a high
total number of pulses (1620 pulses) showed potentially promising
results with regard to the efficacy and safety of this technique in
dogs. The stimulation parameters used significantly decreased in
MSF and MSDF, but not the number of CS post-rTMS compared to
pre-rTMS, within the active rTMS group, which implied that the
overall number and days of epileptic seizure events were decreased,
but the number of CS events was not significantly affected.
Finally, different coil types can achieve different effects with
respect to depth and focal distribution.39 The 8-shaped coil provides
more focal whereas the round coil provides more widespread currents
on the cortical surface.10 Also, vertex stimulation might lead to down-
regulation of excitability within the entire epileptic network, and, thus,
it is likely to provide good outcome in patients with generalized epi-
lepsy.34,40-42 In our study, because the epileptogenic zone responsible
for generating the epileptic seizures was not identified and our
patients suffered from generalized IE rather than a focal epileptogenic
lesion, a round coil was used over the vertex to globally stimulate the
cortex.
F IGURE 3 Illustration of the 3-month pre-rTMS and post-rTMS MSF and MSDF for each dog in the sham group
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Although our results highlighted the promising potential and
importance of investigating this new noninvasive neurostimulation
technique as a treatment option for dogs with drug-resistant IE, our
study had some limitations that preclude definitive conclusions. Spe-
cifically, the low number of included subjects does not allow strong
evidence-based conclusions about the technique's efficacy. In addi-
tion, the results derived from trial II, although positive, have high risk
of bias because trial II was an open-label nonrandomized uncontrolled
clinical trial. However, our study provides new insight into the non-
pharmacological treatment of drug-resistant IE in dogs and encour-
ages further evaluation of rTMS in future large-scale veterinary
studies.
5 | CONCLUSION
We presented preliminary evidence on the potential antiepileptic
effect of rTMS in epileptic dogs that received active stimulation
because such an effect was not shown in dogs that received sham
rTMS, although the small study population did not allow sufficiently
powered results to detect a statistical difference between the groups.
Evidence also was provided to support the safety profile of this tech-
nique in dogs. Because the stimulation parameters used are critical for
the extent and duration of antiepileptic effect, altering and optimizing
the stimulation protocols on an individual basis might lead to longer
lasting effects. Large-scale trials in epileptic dogs evaluating this non-
invasive neurostimulation technique and optimizing the stimulation
protocols should be performed to substantiate our results and provide
definitive conclusions with respect to the efficacy or rTMS in dogs
with drug-resistant IE.
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